Quanterix Corporation (QTRX)
Nasdaq · Healthcare · Medical Devices
$3.81+4.67%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $180M
- 52-week range
- $2.15 – $8.77
- 52-week change
- −38.10%
- EPS (trailing)
- −$2.73
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $139M (+1.08%)
- Net income
- −$107M
- Operating margin
- −90.4%
- Diluted EPS
- −$2.51
- Free cash flow
- −$79.8M
From the company’s annual report on SEC EDGAR.
About Quanterix Corporation
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation.
Headquarters: Billerica, United States · 450 employees · quanterix.com